|
Online View
|
|
|
|
PROTAC®:
A New Frontier in Targeted Therapy
|
|
|
|
PROTAC® technology utilizes E3 ligases to selectively target and degrade pathogenic proteins, addressing drug resistance and “undruggable” targets. Key E3 ligases like CRBN and VHL drive breakthroughs in cancer and other therapies. SignalChem Biotech, part of Sino Biological, provides a wide range of ubiquitin enzymes, including CRBN/DDB1/Cul4A/Rbx1 complexes E1 activating enzymes, E2 conjugating enzymes, E3 ligases, and deubiquitinase enzymes. With over 30 E2 and 600 E3 combinations, SCB’s offerings support cutting-edge drug development.
|
|
Find out More Details 
|
|
Featured Active Ubiquitin Enzymes
|
|
|
|
Wide Reaching Impact
|
|
Remarkable Specificity
|
|
Quality, Support, Trust, and Speed
|
|
|
|
|
|
Cereblon/DDB1/Cul4A/Rbx1 Complex | Cat#: U273-380H
|
|
|
|
View Ubiquitins and PROTAC Poster
|
|
|
|
• Ubiquitin enzymes and PROTACs background
• PROTAC-related molecules and drug overview
• Ubiquitin products used and cited in prominent journals
|
|
|
View Poster Now
|
|
|
 |
